Search
Back

Osimertinib mesylate

CAS 1421373-66-1
Osimertinib mesylate

General Information

Osimertinib mesylate is a methanesulfonate (mesylate) salt prepared from equimolar amounts of osimertinib and methanesulfonic acid. Osimertinib is indicated as a first line treatment of metastatic non-small-cell lung cancer with specific mutations. It demonstrated impressive results in phase IV clinical studies. Here at Teva api, the way we produce the osimertinib API is entirely green, as our ecofriendly and efficient process involves minimal isolation of intermediates. Another huge plus is that we have good control of impurities, especially genotoxic ones.


About the API

Technology Synthetic
Therapeutic category Oncology
Available formulations Oral Solid
Regulations
  • Japan DMF
  • Korea DMF
  • US DMF

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.

For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.